The latest price target for Clover Health Investments (NASDAQ:CLOV) was reported by Leerink Partners on March 5, 2026. The analyst firm set a price target for $2.50 expecting CLOV to rise to within 12 months (a possible 26.21% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Clover Health Investments (NASDAQ:CLOV) was provided by Leerink Partners, and Clover Health Investments maintained their market perform rating.

There is no last upgrade for Clover Health Investments

There is no last downgrade for Clover Health Investments.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clover Health Investments, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clover Health Investments was filed on March 5, 2026 so you should expect the next rating to be made available sometime around March 5, 2027.

While ratings are subjective and will change, the latest Clover Health Investments (CLOV) rating was a maintained with a price target of $3.00 to $2.50. The current price Clover Health Investments (CLOV) is trading at is $1.98, which is out of the analyst’s predicted range.